Equities

Shanghai No.1 Pharmacy Co Ltd

600833:SHH

Shanghai No.1 Pharmacy Co Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (CNY)10.37
  • Today's Change0.03 / 0.29%
  • Shares traded1.75m
  • 1 Year change-17.04%
  • Beta1.1107
Data delayed at least 15 minutes, as of Mar 13 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai No.1 Pharmacy Co Ltd is a China-based company primarily engaged in the retail and wholesale business of pharmaceuticals. The retail business model mainly purchases medicines, food, medical equipment, health convenience products and other commodities from upstream suppliers, and then retails them to end consumers. The wholesale business model mainly purchases medicines and other commodities from upstream suppliers and then sells them to terminal medical institutions or other pharmaceutical and other commodity circulation companies.

  • Revenue in CNY (TTM)1.82bn
  • Net income in CNY89.28m
  • Incorporated1992
  • Employees870.00
  • Location
    Shanghai No.1 Pharmacy Co Ltd20FNo. 681, Xiaomuqiao RoadXuhui DistrictSHANGHAI 200032ChinaCHN
  • Phone+86 2 164337282
  • Fax+86 2 164337191
  • Websitehttp://www.shdyyy.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai No.1 Pharmacy Co Ltd1.82bn89.28m2.50bn870.0027.992.49--1.370.40020.40028.164.490.93254.447.582,091,398.004.585.427.818.9418.6419.044.914.641.16--0.244830.93-31.499.11-37.8113.608.7513.97
HPGC Renmintongtai Pharmaceutical Corp10.33bn298.71m3.83bn2.96k12.831.35--0.37090.51510.515117.824.881.439.312.433,491,425.004.123.9810.5110.879.3010.602.892.731.3324.630.459812.287.778.0510.472.5332.58--
ZhuZhou QianJin Pharmaceutical Co., Ltd3.80bn320.41m4.87bn5.34k15.111.99--1.280.75180.75188.905.710.81593.6815.02711,993.508.488.9916.3416.2145.1244.5910.4010.031.93--0.170768.27-5.662.685.534.64-1.06-2.64
JZJ Chain Drugstore Corp9.31bn449.03m6.18bn15.66k13.772.26--0.66443.483.4872.1721.251.022.8620.14594,079.604.936.758.7213.9835.3635.314.835.150.34755.230.587631.7943.5426.2120.9030.8538.25--
Data as of Mar 13 2024. Currency figures normalised to Shanghai No.1 Pharmacy Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.13%Per cent of shares held by top holders
HolderShares% Held
China Southern Asset Management Co., Ltd.as of 30 Jun 20233.43m1.54%
Essence Fund Co., Ltd.as of 30 Jun 20233.08m1.38%
GF Fund Management Co., Ltd.as of 30 Jun 20233.08m1.38%
Minsheng Royal Fund Management Co., Ltd.as of 30 Jun 2023582.20k0.26%
China Universal Asset Management Co., Ltd.as of 30 Jun 2023414.76k0.19%
PICC Asset Management Co., Ltd.as of 30 Jun 2023388.20k0.17%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023176.00k0.08%
Xingyin Fund Management Co., Ltd.as of 30 Jun 2023166.20k0.08%
Tongtai Fund Management Co., Ltd.as of 30 Jun 2023101.30k0.05%
Guotai Asset Management Co., Ltd.as of 30 Jun 202331.10k0.01%
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.